SAKARPharmaceuticals
Sakar Healthcare Ltd — Profit & Loss Statement
₹498.45
-2.69%
Sakar Healthcare Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | -96110.72 | 0.00 | -0.03 Cr | 0.01 Cr | — |
| Tax Rate For Calcs | 0.19 | 0.27 | 0.24 | 0.20 | — |
| Normalized EBITDA | 51.00 Cr | 41.54 Cr | 37.47 Cr | 31.20 Cr | — |
| Total Unusual Items | -0.05 Cr | 0.00 | -0.12 Cr | 0.06 Cr | — |
| Total Unusual Items Excluding Goodwill | -0.05 Cr | 0.00 | -0.12 Cr | 0.06 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 17.50 Cr | 11.67 Cr | 12.76 Cr | 15.24 Cr | — |
| Reconciled Depreciation | 20.88 Cr | 18.05 Cr | 14.99 Cr | 8.06 Cr | — |
| Reconciled Cost Of Revenue | 82.26 Cr | 83.68 Cr | 73.79 Cr | 74.81 Cr | — |
| EBITDA | 50.94 Cr | 41.54 Cr | 37.35 Cr | 31.26 Cr | — |
| EBIT | 30.06 Cr | 23.49 Cr | 22.36 Cr | 21.60 Cr | — |
| Net Interest Income | -8.54 Cr | -7.59 Cr | -5.70 Cr | -2.91 Cr | — |
| Interest Expense | 8.54 Cr | 7.59 Cr | 5.49 Cr | 2.59 Cr | — |
| Normalized Income | 17.54 Cr | 11.67 Cr | 12.85 Cr | 15.19 Cr | — |
| Net Income From Continuing And Discontinued Operation | 17.50 Cr | 11.67 Cr | 12.76 Cr | 15.24 Cr | — |
| Total Expenses | 148.78 Cr | 133.04 Cr | 114.24 Cr | 107.59 Cr | — |
| Diluted NI Availto Com Stockholders | 17.50 Cr | 11.67 Cr | 12.76 Cr | 15.24 Cr | — |
| Net Income Common Stockholders | 17.50 Cr | 11.67 Cr | 12.76 Cr | 15.24 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 17.50 Cr | 11.67 Cr | 12.76 Cr | 15.24 Cr | — |
| Minority Interests | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income Including Noncontrolling Interests | 17.50 Cr | 11.67 Cr | 12.76 Cr | 15.24 Cr | — |
| Net Income Discontinuous Operations | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income Continuous Operations | 17.50 Cr | 11.67 Cr | 12.76 Cr | 15.24 Cr | — |
| Tax Provision | 4.03 Cr | 4.23 Cr | 4.12 Cr | 3.77 Cr | — |
| Pretax Income | 21.53 Cr | 15.90 Cr | 16.88 Cr | 19.01 Cr | — |
| Other Non Operating Income Expenses | 1.31 Cr | 3.18 Cr | 4.67 Cr | 0.06 Cr | — |
| Special Income Charges | -0.05 Cr | 0.00 | -0.12 Cr | 0.00 | — |
| Net Non Operating Interest Income Expense | -8.54 Cr | -7.59 Cr | -5.70 Cr | -2.91 Cr | — |
| Interest Expense Non Operating | 8.54 Cr | 7.59 Cr | 5.49 Cr | 2.59 Cr | — |
| Operating Income | 28.80 Cr | 20.31 Cr | 19.12 Cr | 20.64 Cr | — |
| Operating Expense | 66.52 Cr | 49.36 Cr | 40.45 Cr | 32.77 Cr | — |
| Other Operating Expenses | 13.99 Cr | 11.53 Cr | 7.57 Cr | 7.76 Cr | — |
| Depreciation And Amortization In Income Statement | 20.88 Cr | 18.05 Cr | 14.99 Cr | 9.67 Cr | — |
| Depreciation Income Statement | 20.88 Cr | 18.05 Cr | 14.99 Cr | 8.94 Cr | — |
| Gross Profit | 95.32 Cr | 69.67 Cr | 59.57 Cr | 53.41 Cr | — |
| Cost Of Revenue | 82.26 Cr | 83.68 Cr | 73.79 Cr | 74.81 Cr | — |
| Total Revenue | 177.58 Cr | 153.35 Cr | 133.36 Cr | 128.23 Cr | — |
| Operating Revenue | 177.58 Cr | 153.35 Cr | 133.36 Cr | 128.23 Cr | — |
| Interest Income | — | 0.13 Cr | 0.27 Cr | 0.00 | 0.02 Cr |
| Diluted Average Shares | — | 2.07 Cr | 1.86 Cr | 1.51 Cr | 0.02 Cr |
| Basic Average Shares | — | 2.07 Cr | 1.86 Cr | 1.51 Cr | 0.02 Cr |
| Diluted EPS | — | 5.63 | 6.86 | 10.09 | 708.58 |
| Basic EPS | — | 5.64 | 6.86 | 10.09 | 708.58 |
| Write Off | — | 0.00 | 0.12 Cr | 0.00 | — |
| Total Other Finance Cost | — | 0.87 Cr | 0.47 Cr | 0.32 Cr | 2.32 Cr |
| Interest Income Non Operating | — | 0.13 Cr | 0.27 Cr | 0.00 | 0.02 Cr |
| Amortization | — | 0.10 Cr | 0.00 | 0.73 Cr | 2.55 Cr |
| Research And Development | — | 0.62 Cr | 0.75 Cr | 0.11 Cr | 0.01 Cr |
| Selling General And Administration | — | 2.16 Cr | 1.21 Cr | 0.90 Cr | 0.95 Cr |
| Selling And Marketing Expense | — | 65000.00 | 0.03 Cr | 0.02 Cr | 55000.00 |
| General And Administrative Expense | — | 2.16 Cr | 1.19 Cr | 0.88 Cr | 0.94 Cr |
| Other Special Charges | — | — | 51000.00 | — | — |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Sakar Healthcare Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.